Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Released on January 7, 2000 and published on-line by the AIDS Treatment Information Service.
Note: Text that is either bold or highlighted represents material added or changed for this version.

Summary
Introduction
Background
Monitoring of Pediatric HIV Infection
Treatment Recommendations
Changing Antiretroviral Therapy
Managing Adverse Drug Reactions in the Therapy of Pediatric HIV Infection
Conclusion
References
Appendix: Characteristics of Available Antiretroviral Drugs

Table I. 1994 Revised Human Immunodeficiency Virus Pediatric Classification System: Immune Categories Based on Age-Specific CD4⁺ T-Lymphocyte and Percentage
Table II. 1994 Revised Human Immunodeficiency Virus Pediatric Classification System: Clinical Categories
Table III. Association of Baseline CD4⁺ T-Lymphocytes Percentage with Long-Term Risk for Death in Human Immunodeficiency Virus (HIV)-Infected Children
Table IV. Association of Human Immunodeficiency Virus (HIV) RNA Copy Number with Long-Term Risk for Death in HIV-Infected Children
Table V. Association of Baseline Human Immunodeficiency Virus (HIV) RNA Copy Number and CD4⁺ T-Lymphocyte Percentage with Long-Term Risk for Death in HIV-Infected Children
Table VI. Association of Baseline Human Immunodeficiency Virus (HIV) RNA Quartile by Age at Entry with Risk for Disease Progression or Death During Study Follow-Up Among HIV-Infected Children Receiving Antiretroviral Treatment
Table VII. Indications for Initiation of Antiretroviral Therapy in Children with Human Immunodeficiency Virus (HIV) Infection
Table VIII. Recommended Antiretroviral Regimens for Initial Therapy for Human Immunodeficiency Virus (HIV) Infection in Children
Table IX. Considerations for Changing Antiretroviral Therapy for Human Immunodeficiency Virus (HIV)-Infected Children